SPOTLIGHT: Genentech licenses Exelixis therapy
Genentech and Exelixis have agreed to a global development pact for XL-518, an MEK-inhibitor for tumors. Exelixis stands to gain up to $40 million in milestones and an upfront fee. Exelixis is responsible for Phase I development. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
